I78-tfw_yef-dg_rt

About I78-tfw_yef-dg_rt

This author has not yet filled in any details.
So far I78-tfw_yef-dg_rt has created 21 blog entries.

Oncotartis raised $1.85 million in a Series B financing from its original investor – Bioprocess Capital Ventures. Proceeds will be used to complete all IND-enabling works and prepare for IND submission.

July 1st, 2016|

OncoTartis has initiated OT-82 GLP Toxicology and Safety Pharmacology studies at Pharmaron, Ltd., US FDA-inspected Clinical Research Organization.

June 27th, 2016|

Pediatric Preclinical Testing Consortium (PPTC) funded by the National Cancer Institute has selected drug candidate OT-82 to be tested in multiple xenograft models of pediatric ALL (Acute Lymphocytic Leukemia).

PPTC  is a multi-center consortium that is testing newly developed drugs against a broad range of childhood malignancies for acceleration into clinical trials.

March 15th, 2016|

Children’s Cancer Institute of Australia for Medical Research has become a shareholder of Oncotartis and one of its strategic research partners.

April 15th, 2015|

Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research (CCIA) initiated testing of OT-82 in systemic preclinical models based on patient-derived cells from pediatric ALL patients with rearranged Mixed Lineage Leukemia gene.

March 30th, 2015|

OncoTartis completed a non-GLP formal toxicology study of OT-82 on rats (21 day) and monkeys (28 days) and successfully determined a safe dose range for human clinical studies. These studies are planned to be repeated under GLP conditions starting in 1Q15.

October 30th, 2014|

Nanosyn, Inc., a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale.

May 16th, 2014|

OncoTartis expanded its research facility by adding more than 2,300 square feet of the new custom-built laboratories equipped for a regular scientific bench work, as well as for testing cultured cancer cells response to discovered anti-cancer compounds.

April 1st, 2014|

The Innovation Center started conversion of a vacant space adjacent to OncoTartis facilities into biological laboratories. Project completion is expected in March 2014.

November 19th, 2013|

OncoTartis relocates to the Innovation Center at Buffalo Niagara Medical Campus. Company’s laboratories and offices occupy 3,000 square feet at 640 Ellicott Street, Buffalo, New York.

February 27th, 2013|